Advertisement
Advertisement
DBL Potassium Dihydrogen Phosphate

DBL Potassium Dihydrogen Phosphate

potassium phosphate

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
K dihydrogen phosphate
Indications/Uses
Severe hypophosphataemia (serum levels <0.3 mmol/L) & other degrees of hypophosphataemia when oral therapy is not possible.
Dosage/Direction for Use
Adult Up to 10 mmol phosphate over 12 hr, may be repeated at 12-hr intervals until serum phosphate exceeds 0.3 mmol/L. Childn 0.15-0.33 mmol/kg over 6 hr, may be repeated at 6-hr intervals until serum phosphate exceeds 0.6 mmol/L. Rate of infusion: Not to exceed 0.2 mmol/kg/hr.
Contraindications
Hyperphosphataemia, hypocalcaemia, hyperkalaemia, Addison's disease, urolithiasis, ventricular fibrillation, hyperadrenalism associated w/ adrenogenital syndrome, extensive tissue breakdown eg, severe burns; acute dehydration, heat cramps, increased sensitivity to K administration eg, adynamia episodica hereditaria or congenital paramytonia. Severe renal impairment, renal impairment w/ oliguria & azotaemia.
Special Precautions
Adrenal insufficiency, diseases associated w/ heart block; hypoparathyroidism, acute dehydration, pancreatitis, rhabdomyolysis, extensive tissue damage eg, severe burns; osteomalacia, rickets, myotonia congenita, heart disease particularly in digitalised patients; hypocalcaemia. Bone binding sites saturation. Monitor serum Na, K, phosphate, Ca conc & renal function every 12-24 hr during therapy. Avoid monobasic K phosphates in hyperkalaemic patients. Not to be administered concomitantly w/ Al, Ca or Mg salts. Chronic renal disease, severe renal insufficiency. Not recommended during pregnancy & lactation.
Adverse Reactions
Hypotension, fluid retention, hyperkalaemia, hypernatraemia, hyperphosphataemia, hypocalcaemia or hypomagnesaemia, extraskeletal calcification eg, nephrocalcinosis in childn.
Drug Interactions
Hyperkalaemia w/ ACE inhibitors, digitalis glycosides, K-sparing diuretics, NSAIDs, other K-containing medicines. Increased risk of Ca deposition in soft tissues w/ Ca-containing medicines. Hyperphosphataemia w/ other phosphate-containing medicines. Increased salicylates serum conc. Incompatibility w/ Ca-, Mg-, Fe- or Al-containing soln.
MIMS Class
Electrolytes
ATC Classification
B05XA06 - potassium phosphate, incl. combinations with other potassium salts ; Belongs to the class of electrolyte solutions used in I.V. solutions.
Presentation/Packing
Form
DBL Potassium Dihydrogen Phosphate inj conc 136.1 mg/mL
Packing/Price
10 mL x 10 × 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement